Jelle Dylus - Concepedia

Author

Jelle Dylus

Also Known As

J. Dylus, Jelle Dylus

Publications

167

Citations

H-Index

Concepts

All Affiliations

Jelle Dylus is an author at Center for Translational Molecular Medicine specializing in cancer research, cell signaling, and immunology.

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	46
2	Cell Biology	1	1	46
3	Immunology	1	1	46
4	Cell Signaling	1	1	46
5	Cancer Research	1	1	46

Jelle Dylus

Publications

161

Citations

H-Index

Page 1

	Year	Citations
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance Jordy C.G. van der Zwet, Jessica G. C. A. M. Buijs-Gladdines, Valentina Cordo’, Leukemia Hematological MalignancyCentral PathwayMixed-phenotype Acute LeukemiaReceptor Tyrosine KinaseMalignant Blood Disorder	2021	46
Stable aneuploid tumors cells are more sensitive to TTK inhibition than chromosomally unstable cell lines Marion A.A. Libouban, Jeroen A.D.M. de Roos, Joost C.M. Uitdehaag, Oncotarget	2017	37
Combined Cellular and Biochemical Profiling to Identify Predictive Drug Response Biomarkers for Kinase Inhibitors Approved for Clinical Use between 2013 and 2017 Joost C.M. Uitdehaag, Jeffrey J. Kooijman, Jeroen A.D.M. de Roos, Molecular Cancer Therapeutics	2018	27
Comparative kinase and cancer cell panel profiling of kinase inhibitors approved for clinical use from 2018 to 2020 Jeffrey J. Kooijman, Wilhelmina E. van Riel, Jelle Dylus, Frontiers in Oncology	2022	20
Cell Panel Profiling Reveals Conserved Therapeutic Clusters and Differentiates the Mechanism of Action of Different PI3K/mTOR, Aurora Kinase and EZH2 Inhibitors Joost C.M. Uitdehaag, Jeroen A.D.M. de Roos, Martine B.W. Prinsen, Molecular Cancer Therapeutics	2016	18
Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites Judith E. den Ouden, Guido J.R. Zaman, Jelle Dylus, Oncotarget	2020	13

Page 1